MLYS 13.89 Mineralys Therapeutics, Inc.
| Range: | 5.85-16.905 | Vol Avg: | 182926 | Last Div: | 0 | Changes: | 0.14 |
| Beta: | 2.46 | Cap: | 0.67B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 10 2023 | Empoloyees: | 28 | ||
| CUSIP: | 603170101 | CIK: | 0001933414 | ISIN: | US6031701013 | Country: | US |
| CEO: | Mr. Jon Congleton | Website: | https://mineralystx.com | ||||
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Stock Details
Positive 0.21
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC i...
accesswire.com·Tue Sep 24 2024
Positive 0.21
Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 23, 2024 / Bronstein, Gewirtz & Grossman, LLC i...
accesswire.com·Mon Sep 23 2024
Positive 0.21
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, Sept. 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising-- NEW YORK--(PR NEWSWIRE...
globenewswire.com·Sun Sep 22 2024
Positive 0.13
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK--(BUSINESS WIRE)---- $MLYS #classaction--Attorney Advertising--Bronstein, Gewirtz...
businesswire.com·Fri Sep 20 2024
Positive 0.21
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC i...
accesswire.com·Wed Sep 18 2024
Positive 0.17
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in trea...
seekingalpha.com·Tue Sep 17 2024
Positive 0.21
Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 17, 2024 / Bronstein, Gewirtz & Grossman, LLC i...
accesswire.com·Tue Sep 17 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow